PIPELINE OVERVIEW

Aptose Biosciences is a clinical-stage biotechnology company with two active preclinical/clinical-stage programs, and a third program that is discovery-stage and positioned for partnering. Aptose’s pan-FLT3 / BTK program, CG’806, is currently in preclinical development and moving toward IND submission, with anticipation of commencing a Phase 1 trial the first half of 2018. APTO-253 is Aptose’s second program and at the Phase 1b clinical stage for the treatment of patients with relapsed / refractory blood cancers, including AML and high-risk MDS under an IND allowed by the U.S. FDA to evaluate APTO-253 as a therapeutic agent dosed on a weekly administration schedule for the treatment of certain hematologic malignancies.